Literature DB >> 24890688

Decatenation checkpoint-defective melanomas are dependent on PI3K for survival.

Kelly Brooks1, Max Ranall, Loredana Spoerri, Alex Stevenson, Gency Gunasingh, Sandra Pavey, Fred Meunier, Thomas J Gonda, Brian Gabrielli.   

Abstract

Melanoma cell lines are commonly defective for the G2-phase cell cycle checkpoint that responds to incomplete catenation of the replicated chromosomes. Here, we demonstrate that melanomas defective for this checkpoint response are less sensitive to genotoxic stress, suggesting that the defective cell lines compensated for the checkpoint loss by increasing their ability to cope with DNA damage. We performed an siRNA kinome screen to identify kinases responsible and identified PI3K pathway components. Checkpoint-defective cell lines were three-fold more sensitive to small molecule inhibitors of PI3K. The PI3K inhibitor PF-05212384 promoted apoptosis in the checkpoint-defective lines, and the increased sensitivity to PI3K inhibition correlated with increased levels of activated Akt. This work demonstrates that increased PI3K pathway activation is a necessary adaption for the continued viability of melanomas with a defective decatenation checkpoint.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PI3K; decatenation checkpoint; melanoma; synthetic lethality

Mesh:

Substances:

Year:  2014        PMID: 24890688     DOI: 10.1111/pcmr.12268

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  5 in total

1.  Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Authors:  Batool Shannan; Quan Chen; Andrea Watters; Michela Perego; Clemens Krepler; Rakhee Thombre; Ling Li; Geena Rajan; Scott Peterson; Phyllis A Gimotty; Melissa Wilson; Katherine L Nathanson; Tara C Gangadhar; Lynn M Schuchter; Ashani T Weeraratna; Meenhard Herlyn; Adina Vultur
Journal:  Pigment Cell Melanoma Res       Date:  2016-03-21       Impact factor: 4.693

Review 2.  Targeting the Checkpoint to Kill Cancer Cells.

Authors:  Jan Benada; Libor Macurek
Journal:  Biomolecules       Date:  2015-08-18

3.  Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.

Authors:  Jacquelyn J Bower; Leah D Vance; Matthew Psioda; Stephanie L Smith-Roe; Dennis A Simpson; Joseph G Ibrahim; Katherine A Hoadley; Charles M Perou; William K Kaufmann
Journal:  NPJ Breast Cancer       Date:  2017-03-31

4.  Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.

Authors:  Alexander J Stevenson; Eleanor I Ager; Martina A Proctor; Dubravka Škalamera; Andrew Heaton; David Brown; Brian G Gabrielli
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

5.  A genome-wide RNAi screen identifies the SMC5/6 complex as a non-redundant regulator of a Topo2a-dependent G2 arrest.

Authors:  Katharina Deiss; Nicola Lockwood; Michael Howell; Hendrika Alida Segeren; Rebecca E Saunders; Probir Chakravarty; Tanya N Soliman; Silvia Martini; Nuno Rocha; Robert Semple; Lykourgos-Panagiotis Zalmas; Peter J Parker
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.